Steroid-induced CSC may only occur in vulnerable patients

Article

Steroid-induced central serous chorioretinopathy (CSC) may only occur in select patients who are vulnerable, rather than having a dose-dependent effect, according to a recent study published in Investigative Ophthalmology & Visual Science

Steroid-induced central serous chorioretinopathy (CSC) may only occur in select patients who are vulnerable, rather than having a dose-dependent effect, according to a recent study published in Investigative Ophthalmology & Visual Science.

For this prospective, pilot study, researchers from the Seoul National University College of Medicine and Bundang Hospital measured choroidal thickness in 35 eyes in 18 patients treated with high-dose systemic corticosteroid pulse therapy (>500 mg/d) at baseline, 1 day, 1 week and 1 month after corticosteroids were administered. Blood pressures were measured four times daily for the first 5 days of treatment as well. High-dose corticosteroid therapy concentrations delivered were 19.5 mg/kg, for a mean of 5.2 days.

At baseline, the mean subfoveal choroidal thickness was 259.8 μm (range: 86.4 to 394.7 μm). No significant changes in choroidal thickness were seen at day 1, week 1, or month 1 after treatment (P = 0.117). In only one patient who presented at baseline with pigment epithelial detachment, bilateral focal subretinal fluid was seen and showed central serous chorioretinopathy, with a 13.1% increase in subfoveal choroidal thickness.

To view an abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.